Bellus Health Inc. - a GSK company

Related records

Trials (19)

• A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
• A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
• A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough
• A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis
• A Phase IIa Proof-of-concept Study of NC-503 in Patients With Type II Diabetes
• A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of Age
• A Study to Investigate the Effect of Food on Camlipixant Concentrations in Healthy Participants
• Assessment of the Pharmacokinetics of BLU-5937 Extended Release Prototypes and a BLU-5937 Immediate Release Reference Formulation
• BLU-5937: First-in-Human, Single and Multiple Doses Escalation, Safety, Tolerability, Pharmacokinetics and Food Effect
• Cerebril™ in Patients With Lobar Hemorrhage Related to Cerebral Amyloid Angiopathy
• European Study of 3APS in Mild to Moderate Alzheimer's Disease Patients
• Evaluation of 3APS in Patients With Mild to Moderate Alzheimer's Disease
• Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant
• Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
• Evaluation of the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects
• Evaluation of the Potential Drug-drug Interactions Between Gemfibrozil or Dabigatran Etexilate and Camlipixant
• Mass Balance Recovery, Absorption, Metabolism and Excretion of [14C]-BLU-5937
• Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's Disease
• Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis